|
MGTX | Meiragtx Holdings Plc |
|
|
MGTX | Meiragtx Holdings Plc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.08 |
| Leverage | 121.41% |
| Market Cap | $ 491.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -168.1m |
| Margin | -662.64% |
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.